Medable, a clinical trial technology platform provider, has launched Medable Studio, an all-in-one application for configuring, translating, validating, and launching electronic clinical outcome assessment (eCOA) Plus solutions (which include eCOA, e-consent, televisits, and sensors) into clinical trials. The no-code suite aims to simplify the complex eCOA launch process, offering biopharmaceutical companies greater control and transparency.

Medable Studio includes a point-and-click builder for creating assessments and instruments, a visual schedule of assessments builder, a translation workbench, and a content library. The platform enables users to rapidly build and launch complex clinical trials, with the ability to create protocol-fit study designs in hours instead of months.

According to Medable, the new solution will set new benchmarks for trial execution by reducing trial startup timelines and costs. As of August 2024, the company claims that its customers have achieved results such as 200% faster enrollment and 50% cost reductions using the platform.

Analyst QuickTake : Earlier, in May 2024 , the company partnered with Masimo to incorporate wearable devices in decentralized trials for cancer. Through the partnership, Medable began including Masimo’s MightySat Rx pulse oximeter in its platform for various major clinical trials, particularly in lung and breast cancer research. With the release of its Medable Studio solution, the company has the potential to form similar partnerships in the future, as its platform is now better suited to incorporate sensors and other technology into the clinical trial process.